

REMARKS

Claim Amendments

Claims 194, 196, 198-206, 209-215, 217-256 and 310-317 are pending. Claim 194 is amended herein. Support for this amendment can be found throughout the application as filed. *See e.g.*, paragraphs [0166] and [0236]. Claims 310-317 were previously amended by Examiner's Amendment. No new matter has been added.

Specification Amendments

Applicants have amended the specification to update the priority information and correct minor, typographical errors. Applicants have also amended paragraph [0047] to change "10b" to "10L," as Figure 10 contains images A-L. Paragraph [0254] was amended to correct an Accession number. No new matter has been added.

Drawings

In the Examiner's Comments mailed on June 28, 2007, the Examiner requests that Applicants amend the legend of Figure 9 to only describe Figures 9A and 9B. The Examiner also asserts that while the specification describes Figures 10A, 10B, 16A and 16B, the drawings do not contain these labeled figures.

Applicants respectfully submit that the formal drawings filed on October 12, 2004 remedy the Examiner's concerns. Nonetheless, in an effort to expedite issuance, Applicants submit herewith formal drawings and request that these figures be published when the instant application issues. Applicants believe these formal figures are in compliance with 37 C.F.R. § 1.84 and address the Examiner's concerns. Applicants respectfully request that the Examiner notify Applicants if there are any objections to these formal drawings.

Statement of Substance of Interview Under 37 C.F.R. § 1.133(b)

In accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04, Applicants herein provide a summary of the interview. Applicants appreciate the courtesies extended by Examiner Landsman.

During the interview, Examiner Landsman requested that Applicants amend claim 194 to recite that the T1R2/T1R3 receptor specifically binds to a ligand that specifically binds to an endogenous (wild-type) human T1R2/T1R3 receptor comprised of at least one endogenous T1R2

polypeptide and at least one endogenous T1R3 polypeptide. Applicants have amended claim 194 herein to reflect this addition.

Applicants representative also indicated that Applicants would identify other co-pending applications that relate to the instant application. Below is a list of these applications:

Application Nos. 10/179,373; 10/725,037; 10/725,076; 10/725,080; 10/725,103; 10/725,418; 10/725,472; 10/725,473; 10/725,488; 10/725,489 and 11/050,804.

CONCLUSION

Applicants respectfully request entry and consideration of the above amendments and remarks. If the Examiner has any questions relating to this response or the application in general he is respectfully requested to contact the undersigned so that prosecution of this application may be expedited.


It is believed that no fees are required for entry of this response, but should any fees be necessary, the Commissioner is authorized to charge such fees to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS, LLP

Dated: September 24, 2007

By:



Robin L. Teskin
Registration No. 35,030

Alexander H. Spiegler
Registration No. 56,625

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W. Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

RLT/AHS:ltm